Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lea Felderer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Expert Opinion on Pharmacotherapy|May 10, 2013
Basal cell carcinoma: a paradigm for targeted therapiesJil Dreier, Lea Felderer, Marjam Barysch, et al.
Expert Opinion on Emerging Drugs|April 30, 2014
Emerging drugs and combination strategies for basal cell carcinomaJil Dreier, Reinhard Dummer, Lea Felderer, et al.
Dermatology (Basel, Switzerland)|April 8, 2016
Nevoid Basal Cell Carcinoma Syndrome: Report from the Zurich Nevoid Basal Cell Carcinoma Syndrome CohortSusanne Rehefeldt-Erne, Mirjam C Nägeli, Nina Winterton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinomaAtsushi Otsuka, Jil Dreier, Phil F Cheng, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2013
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot studyReinhard Dummer, Simone M Goldinger, Christian P Turtschi, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|May 10, 2013
Basal cell carcinoma: a paradigm for targeted therapiesJil Dreier, Lea Felderer, Marjam Barysch, et al.
Expert Opinion on Emerging Drugs|April 30, 2014
Emerging drugs and combination strategies for basal cell carcinomaJil Dreier, Reinhard Dummer, Lea Felderer, et al.
Dermatology (Basel, Switzerland)|April 8, 2016
Nevoid Basal Cell Carcinoma Syndrome: Report from the Zurich Nevoid Basal Cell Carcinoma Syndrome CohortSusanne Rehefeldt-Erne, Mirjam C Nägeli, Nina Winterton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinomaAtsushi Otsuka, Jil Dreier, Phil F Cheng, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2013
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot studyReinhard Dummer, Simone M Goldinger, Christian P Turtschi, et al.
Pageof 1